InsightRX, Premier Partner to Develop Precision Antibiotics Solution

99
Clinical decision support software developer InsightRX will partner with Premier, a healthcare improvement company with 4,000 member U.S. hospitals and health systems, on a precision medicine collaboration designed to individualize medication dosing for drugs used in treating infectious disease. The collaboration will integrate Insight RX's cloud-based precision dosing platform, InsightRX Nova (pictured), with Premier's clinical surveillance technology. [InsightRX]

Clinical decision support software developer InsightRX said today it will partner with Premier, a healthcare improvement company with 4,000 member U.S. hospitals and health systems, on a precision medicine collaboration designed to individualize medication dosing for drugs used in treating infectious disease.

The collaboration, whose value was not disclosed, will integrate InsightRX’s cloud-based precision dosing platform, InsightRX Nova, with Premier’s clinical surveillance technology, powered by TheraDoc, a provider of electronic clinical surveillance system software applications with operations in Charlotte, NC, and Salt Lake City, UT.

The companies said they aim to create a comprehensive, easy-to-use solution that will enable clinicians to tailor dosages of vancomycin and other complex antibiotics to their individual patients.

“The InsightRX Nova® platform combined with Premier’s world-class clinical surveillance product will enable healthcare providers to streamline data entry, while helping pharmacists and clinicians offer best-in-class patient care to those suffering from infectious diseases,” Sirj Goswami, Ph.D., CEO and co-founder of InsightRX, said in a statement.

InsightRX’s platform is designed to guide clinician treatment decisions by leveraging patient-specific data, pharmacology models, and machine learning. For biopharma users, InsightRX assists in perfecting drugs through development and clinical trial phases by optimizing efficacy and safety at the patient level.

The integrated solution will help clinicians determine an individualized, effective and safe antimicrobial dose with greater accuracy using quantitative pharmacology models and Bayesian forecasting—as well as identify at-risk patients, according to InsightRX and Premier.

In addition, the combined precision medicine solution will support compliance with upcoming vancomycin dosing and monitoring guidelines to be jointly published by the American Society of Hospital Pharmacists (ASHP), Infectious Disease Society of America (IDSA), Pediatric Infectious Disease Society (PIDS), and Society of Infectious Disease Pharmacists (SIDP).

“We established this partnership with InsightRX to increase access to precision dosing for more than 1,100 hospitals. Clinicians need access to tools that give them the ability to more effectively dose high risk antimicrobials,” added Michelle Allen, vice president and general manager of clinical solutions at Premier. “We look forward to working with InsightRX to help individualize therapy for infectious diseases and hope to expand our partnership to enable precision dosing across a number of therapeutic areas.”

Premier oversees an alliance of more than 4,000 U.S. hospitals and health systems and approximately 175,000 other providers and organizations seeking better care and outcomes at a lower cost through the company’s integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services.

This site uses Akismet to reduce spam. Learn how your comment data is processed.